IBU
LOE ApproachingNDAORALSUSPENSION
Approved
Dec 1989
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
Drug data last refreshed 12h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IBU is an oral suspension small-molecule formulation approved in 1989 by Abbott. The generic name and mechanism of action are not specified in available data, limiting definitive therapeutic characterization. This product represents a mature, established medication in the oral suspension category.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30%), suggesting a consolidating team focused on generic transition planning rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Efficacy and Safety of Cryotherapy Followed by Tirbanibulin Ointment for Actinic Keratosis on the Scalp and Forehead
Started Nov 2026
59 enrolled
KeratosisActinic Keratoses
Establish Whether Hyperangulated Videolaryngoscopy (HAVL) Can be Used to Facilitate Tracheal Intubation Effectively and Safely in Unselected Adult Patients; Describe the Population in Whom HAVL Fails to Facilitate Tracheal Intubation Successfully, Identifying Any Contributory Characteristics.
Started Nov 2026
500 enrolled
Intubation SkillIntubation ComplicationsIntubation With Uncuffed Endotracheal Tube
Absorption, Distribution, Metabolism, and Excretion of 14C-VX-407 After a Single Oral Dose
Started Oct 2026
8 enrolled
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
In Vitro Susceptibility of Dermatophytes to Terbinafine and Itraconazole: MIC Distributions and Elevated-MIC Isolates in Faisalabad, Pakistan
Started Oct 2026
120 enrolled
DermatophytosisTinea CorporisTinea Cruris+2 more
Effects of Orofacial Myofunctional Therapy and Cervical Stabilization Exercises in Patients With Axis-i Group Iia Temporomandibular Dysfunction
Started Oct 2026
88 enrolled
Temporo-mandibular DysfunctionDisc DisplacementAxis I Diagnosis+1 more
Worked on IBU at Abbott? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.